James D. Liddil

481 total citations
19 papers, 427 citations indexed

About

James D. Liddil is a scholar working on Molecular Biology, Toxicology and Organic Chemistry. According to data from OpenAlex, James D. Liddil has authored 19 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 8 papers in Toxicology and 4 papers in Organic Chemistry. Recurrent topics in James D. Liddil's work include Cancer therapeutics and mechanisms (12 papers), Bioactive Compounds and Antitumor Agents (8 papers) and Synthesis and Biological Evaluation (4 papers). James D. Liddil is often cited by papers focused on Cancer therapeutics and mechanisms (12 papers), Bioactive Compounds and Antitumor Agents (8 papers) and Synthesis and Biological Evaluation (4 papers). James D. Liddil collaborates with scholars based in United States and China. James D. Liddil's co-authors include Robert T. Dorr, David S. Alberts, G. Timothy Bowden, R T Dorr, Philip Scuderi, George S. Wilson, J. Richard Sportsman, C. Kent Osborne, Daniel D. Von Hoff and William S. Dalton and has published in prestigious journals such as Journal of Clinical Oncology, Analytical Chemistry and European Journal of Immunology.

In The Last Decade

James D. Liddil

19 papers receiving 406 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James D. Liddil United States	12	253	97	86	54	50	19	427
Marek Šarišský Slovakia	15	245 1.0×	129 1.3×	49 0.6×	40 0.7×	24 0.5×	25	530
Jin Yin China	11	301 1.2×	107 1.1×	107 1.2×	76 1.4×	29 0.6×	15	520
R.E.C. Henrar Netherlands	14	244 1.0×	116 1.2×	125 1.5×	62 1.1×	13 0.3×	23	448
Hidee Ishii Japan	11	148 0.6×	75 0.8×	100 1.2×	19 0.4×	87 1.7×	33	402
Takayuki Yamazaki Japan	15	389 1.5×	208 2.1×	66 0.8×	12 0.2×	49 1.0×	21	592
Gabriela Kořínková Czechia	8	381 1.5×	49 0.5×	183 2.1×	36 0.7×	31 0.6×	12	501
José D. Solano Mexico	13	233 0.9×	159 1.6×	59 0.7×	25 0.5×	14 0.3×	22	450
J. E. Sodergren United States	9	267 1.1×	61 0.6×	118 1.4×	32 0.6×	22 0.4×	12	560
Rahul Agarwal India	15	246 1.0×	185 1.9×	74 0.9×	28 0.5×	34 0.7×	31	518
Yiding Hu United States	14	121 0.5×	71 0.7×	95 1.1×	15 0.3×	53 1.1×	22	465

Countries citing papers authored by James D. Liddil

Since Specialization

Citations

This map shows the geographic impact of James D. Liddil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James D. Liddil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James D. Liddil more than expected).

Fields of papers citing papers by James D. Liddil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James D. Liddil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James D. Liddil. The network helps show where James D. Liddil may publish in the future.

Co-authorship network of co-authors of James D. Liddil

This figure shows the co-authorship network connecting the top 25 collaborators of James D. Liddil. A scholar is included among the top collaborators of James D. Liddil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James D. Liddil. James D. Liddil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Dorr, Robert T., et al.. (2001). Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators. Anti-Cancer Drugs. 12(3). 213–220. 14 indexed citations

Dorr, Robert T., et al.. (1998). Analytical and biological inequivalence of two commercial formulations of the antitumor agent bleomycin. Cancer Chemotherapy and Pharmacology. 42(2). 149–154. 7 indexed citations

Dorr, Robert T., William Bellamy, James D. Liddil, Amanda F. Baker, & Kenneth W. Bair. (1998). Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols.. PubMed. 13(7). 825–35. 3 indexed citations

Dorr, Robert T., James D. Liddil, Mary K. Klein, & Evan M. Hersh. (1995). Preclinical pharmacokinetics and antitumor activity of imexon. Investigational New Drugs. 13(2). 113–116. 16 indexed citations

Dorr, Robert T. & James D. Liddil. (1995). Stability of mitomycin C in different infusion fluids: Compatibility with heparin and glucocorticosteroids. Journal of Oncology Pharmacy Practice. 1(3). 19–24. 3 indexed citations

Dorr, Robert T., et al.. (1993). The Effect of Anticancer Drug Sequence in Experimental Combination Chemotherapy. Cancer Investigation. 11(1). 15–24. 18 indexed citations

Dorr, Robert T. & James D. Liddil. (1991). Modulation of mitomycin C-induced multidrug resistance in vitro. Cancer Chemotherapy and Pharmacology. 27(4). 290–294. 13 indexed citations

Scuderi, Philip, Robert T. Dorr, James D. Liddil, et al.. (1989). Alpha‐globulins suppress human leukocyte tumor necrosis factor secretion. European Journal of Immunology. 19(5). 939–942. 44 indexed citations

Dorr, Robert T., et al.. (1989). Antitumor activity and murine pharmacokinetics of parenteral acronycine.. PubMed. 49(2). 340–4. 56 indexed citations

10.

Liddil, James D., R T Dorr, & Philip Scuderi. (1989). Association of lysosomal activity with sensitivity and resistance to tumor necrosis factor in murine L929 cells.. PubMed. 49(10). 2722–8. 34 indexed citations

11.

Dorr, R T & James D. Liddil. (1988). Development of a parenteral formulation for the anti-tumour agent acronycine. 1(1). 31–39. 7 indexed citations

12.

Dorr, R T, D S Alberts, & James D. Liddil. (1988). Mitomycin C toxicity and pharmacokinetics in mice given sulfur nucleophiles.. PubMed. 8(4). 733–7. 2 indexed citations

13.

Liddil, James D., et al.. (1987). Mitomycin C resistant L1210 leukemia cells: Association with pleiotropic drug resistance. Biochemical Pharmacology. 36(19). 3115–3120. 34 indexed citations

14.

Dorr, R T, et al.. (1986). Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide.. Journal of Clinical Oncology. 4(9). 1399–1404. 13 indexed citations

15.

Dorr, Robert T., James D. Liddil, & Eugene W. Gerner. (1986). Modulation of etoposide cytotoxicity and DNA strand scission in L1210 and 8226 cells by polyamines.. PubMed. 46(8). 3891–5. 10 indexed citations

16.

Dorr, Robert T., et al.. (1986). Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells. Investigational New Drugs. 4(4). 305–313. 30 indexed citations

17.

Dorr, R T, James D. Liddil, & Jeffrey M. Trent. (1985). Characterization of a mitomycin C (MMC) resistant L-1210 cell line. Proceedings of the American Association for Cancer Research. 26. 1 indexed citations

18.

Dorr, Robert T., G. Timothy Bowden, David S. Alberts, & James D. Liddil. (1985). Interactions of mitomycin C with mammalian DNA detected by alkaline elution.. PubMed. 45(8). 3510–6. 79 indexed citations

19.

Sportsman, J. Richard, James D. Liddil, & George S. Wilson. (1983). Kinetic and equilibrium studies of insulin immunoaffinity chromatography. Analytical Chemistry. 55(4). 771–775. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact